Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
Stopped This study did not meet the efficacy objective
Conditions
- Sarcoma
- Myxoid/Round Cell Liposarcoma
- Synovial Sarcoma
- Metastatic Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Locally Advanced Sarcoma
- Liposarcoma
Interventions
- BIOLOGICAL: CMB305
- BIOLOGICAL: atezolizumab
Sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborators